Cellectricon signs collaboration agreement with AstraZeneca
05-May-2006
"We are pleased that AstraZeneca sees the value of our microfluidic-based solutions for drug discovery", says Dr. Mattias Karlsson, VP Research & Development at Cellectricon. "The fantastic market acceptance of Dynaflow, our first generation of microfluidic-based tools supports the unique possibilities the micro-scale format offers such as superior performance characteristics and robustness."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.